Skip to main content
Fig. 4 | Journal of Biological Engineering

Fig. 4

From: An innovative lab-scale production for a novel therapeutic DNA vaccine candidate against rheumatoid arthritis

Fig. 4

Identification of the final plasmid products. a The final plasmid extracted using the different processes was subjected to restriction enzyme digestion and analysed using 1% agarose gel electrophoresis (5 V/cm, 45 min). M: DNA Marker (1 kb Plus DNA Marker, MD113, TIANGEN). Lanes 1 and 2: plasmids purified using the PEG/MgCl2 precipitation protocol linearised with HindIII and double-digested with HindIII and EcoRI, respectively. Lanes 3 and 4: plasmids purified using anion exchange chromatography (AEC) linearised with HindIII and double-digested with HindIII and EcoRI, respectively. Lanes 5 and 6: plasmids purified using a commercial kit linearised with HindIII and double-digested with HindIII and EcoRI, respectively. b Extract of a typical chromatogram obtained from sequencing the plasmids obtained in this study

Back to article page